Justine Lopez
Research Subjects
Justine Lopez has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Anja Holtz
Buck Institute for Research on Aging
41 shared publications - Austin Chen
Contineum Therapeutics, 3565 General Atomics Court, Suite 200, San Diego, California 92121, United States
41 shared publications - Brian J. Francica
Tempest Therapeutics, Brisbane, California
41 shared publications - Chan C. Whiting
10Tempest Therapeutics, Brisbane, California
41 shared publications - David Freund
Tempest Therapeutics, Brisbane, California
41 shared publications - David Powell
Chinook Therapeutics, Inc., Seattle, Washington
41 shared publications
Latest Publications
- Open Access
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
TABLE 1B from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
Antibodies used for IHC of APCmin/+ tumors
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 1B from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
Antibodies used for IHC of APCmin/+ tumors
- Open Access
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
TABLE 1C from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
Antibodies used for IHC of CT26 tumors
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 1C from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
Antibodies used for IHC of CT26 tumors
- Open Access
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 6 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
TPST-1495 effectively increases survival and modulates the TME in APCmin/+ mice. A, Tumor counts in the small intestine of APCmin/+ mice. Mice were treated starting at 13 weeks of age for 3 weeks with TPST-1495 (100 mg/kg twice a day, orally), E7046 (150 mg/kg every day, orally), PF04418948 (100 mg/kg every day, orally), or Celecoxib (60 mg/kg every day, orally). Results are representative of multiple experiments with 7–10 mice. B, Kaplan–Meier curve of survival of APCmin/+ mice and log-rank Mantel–Cox P values of listed comparisons. Mice were ages to 13 weeks, then treated with as in A or with the combination of E7046 and PF04418948 at monotherapy doses, for 6 weeks. Survival was monitored longitudinally and mice were sacrificed as they became moribund. Results are representative of two similar experiments with 8 mice per group. C, IHC of tumor or hyperplasia excised from small intestines of mice from experiment in A. Quantification displays values from one tumor in each biological replicate. TPST-1495 every day and twice a day groups are concatenated because of limited tumor tissue in these groups. Mean and SD are depicted in all graphs and the Student two-sided t test was used to assess significance between individual groups. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05. BID, twice a day; QD, every day.
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 6 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
TPST-1495 effectively increases survival and modulates the TME in APCmin/+ mice. A, Tumor counts in the small intestine of APCmin/+ mice. Mice were treated starting at 13 weeks of age for 3 weeks with TPST-1495 (100 mg/kg twice a day, orally), E7046 (150 mg/kg every day, orally), PF04418948 (100 mg/kg every day, orally), or Celecoxib (60 mg/kg every day, orally). Results are representative of multiple experiments with 7–10 mice. B, Kaplan–Meier curve of survival of APCmin/+ mice and log-rank Mantel–Cox P values of listed comparisons. Mice were ages to 13 weeks, then treated with as in A or with the combination of E7046 and PF04418948 at monotherapy doses, for 6 weeks. Survival was monitored longitudinally and mice were sacrificed as they became moribund. Results are representative of two similar experiments with 8 mice per group. C, IHC of tumor or hyperplasia excised from small intestines of mice from experiment in A. Quantification displays values from one tumor in each biological replicate. TPST-1495 every day and twice a day groups are concatenated because of limited tumor tissue in these groups. Mean and SD are depicted in all graphs and the Student two-sided t test was used to assess significance between individual groups. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05. BID, twice a day; QD, every day.
- Open Access
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
TABLE 1C from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
Antibodies used for IHC of CT26 tumors
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 1C from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
Antibodies used for IHC of CT26 tumors
- Open Access
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 3 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
TPST-1495 is more effective than a single EP4 or EP2 antagonists in overcoming PGE2-mediated immune suppression of recovery of cytokine production from human monocytes and T cells. TNFα ELISA from PGE2 blockade assay performed using human whole blood treated with TPST-1495 (A) or E7046 (B) in the presence of 10 nmol/L or 500 nmol/L PGE2. Graphs show one representative donor of 3 donors tested. C–E, IFNγ concentration in supernatants of PGE2 blockade assay performed on magnetically enriched T cells from human PBMC. Cells were treated with various concentrations of EP receptor inhibitors TPST-1495 (C), E7046 (D), or PF04418948 (E), followed by concentrations of PGE2 and CEF peptides as shown in C and D. Cytokine levels in supernatants were determined by bead-based cytokine array analysis. Graphs show data with N = 4 technical replicates from one of four independent experiments. Two different healthy donors were used across these experiments. F, Percent IFNγ production rescue, as normalized to the control (DMSO), from PGE2 Blockade assay supernatants. Magnetically enriched T Cells from human PBMC were treated with increasing amounts of EP1 (Ono-8130) and EP3 (L-798106) inhibitors and subjected to 333 nmol/L PGE2 before stimulation with CEF peptides. Each datapoint represents the average percent recovery from one experiment, with four total experiments shown. G, Percent IFNγ production rescue, as normalized to control with 0 nmol/L PGE2 and 0 nmol/L TPST-1495. Cells obtained as in C–F were treated with increasing TPST-1495 in the presence or absence of 10 mmol/L EP1 inhibitor and 10 mmol/L EP3 inhibitor. Each datapoint represents the average percent recovery from one experiment, with four total experiments shown. Mean and SD are depicted in all graphs and the Student two-sided t test was used to assess significance between individual groups. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05.
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 3 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
TPST-1495 is more effective than a single EP4 or EP2 antagonists in overcoming PGE2-mediated immune suppression of recovery of cytokine production from human monocytes and T cells. TNFα ELISA from PGE2 blockade assay performed using human whole blood treated with TPST-1495 (A) or E7046 (B) in the presence of 10 nmol/L or 500 nmol/L PGE2. Graphs show one representative donor of 3 donors tested. C–E, IFNγ concentration in supernatants of PGE2 blockade assay performed on magnetically enriched T cells from human PBMC. Cells were treated with various concentrations of EP receptor inhibitors TPST-1495 (C), E7046 (D), or PF04418948 (E), followed by concentrations of PGE2 and CEF peptides as shown in C and D. Cytokine levels in supernatants were determined by bead-based cytokine array analysis. Graphs show data with N = 4 technical replicates from one of four independent experiments. Two different healthy donors were used across these experiments. F, Percent IFNγ production rescue, as normalized to the control (DMSO), from PGE2 Blockade assay supernatants. Magnetically enriched T Cells from human PBMC were treated with increasing amounts of EP1 (Ono-8130) and EP3 (L-798106) inhibitors and subjected to 333 nmol/L PGE2 before stimulation with CEF peptides. Each datapoint represents the average percent recovery from one experiment, with four total experiments shown. G, Percent IFNγ production rescue, as normalized to control with 0 nmol/L PGE2 and 0 nmol/L TPST-1495. Cells obtained as in C–F were treated with increasing TPST-1495 in the presence or absence of 10 mmol/L EP1 inhibitor and 10 mmol/L EP3 inhibitor. Each datapoint represents the average percent recovery from one experiment, with four total experiments shown. Mean and SD are depicted in all graphs and the Student two-sided t test was used to assess significance between individual groups. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05.
- Open Access
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
TABLE 1B from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
Antibodies used for IHC of APCmin/+ tumors
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 1B from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
Antibodies used for IHC of APCmin/+ tumors
- Open Access
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 7 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
Effective antagonism of PGE2 signaling modulates significant transcriptional shifts in the TME. A, Volcano plots of selected genes. Blue coloration represents significantly (Padj < 0.05) downregulated genes while red correlation represents significantly upregulated genes. Genes in gray did not meet the significance cutoff. B, Heat map depicting significantly upregulated gene sets from GSEA performed on RNA sequencing analysis above and representative GSEA plot from IFNγ signature. All results represent data from one experiment with 4 animals per group. *** indicates FDR < 0.25 for that gene set compared with vehicle-treated animals.
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 7 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
Effective antagonism of PGE2 signaling modulates significant transcriptional shifts in the TME. A, Volcano plots of selected genes. Blue coloration represents significantly (Padj < 0.05) downregulated genes while red correlation represents significantly upregulated genes. Genes in gray did not meet the significance cutoff. B, Heat map depicting significantly upregulated gene sets from GSEA performed on RNA sequencing analysis above and representative GSEA plot from IFNγ signature. All results represent data from one experiment with 4 animals per group. *** indicates FDR < 0.25 for that gene set compared with vehicle-treated animals.
- Open Access
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 1 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
Expression profiles of PGE2 receptors EP2 and EP4 across diverse human malignancies. A, Expression of EP2 (PTGER2) and EP4 (PTGER4) across cancer indications indicated in the figure using RNA sequencing data from TCGA Pan Cancer dataset obtained through cBIO Portal. Selected cancer types are labeled with TCGA abbreviations. B, Heat map of EP2 and EP4 expression across the selected malignancies, with definition of TCGA tumor type abbreviations defined. C, Heat map analysis of percent positive samples for designated prostaglandin pathway genes, including PTGER4, PTGS2, PTGES2, and PTGES from the Protein Atlas database.
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 1 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
Expression profiles of PGE2 receptors EP2 and EP4 across diverse human malignancies. A, Expression of EP2 (PTGER2) and EP4 (PTGER4) across cancer indications indicated in the figure using RNA sequencing data from TCGA Pan Cancer dataset obtained through cBIO Portal. Selected cancer types are labeled with TCGA abbreviations. B, Heat map of EP2 and EP4 expression across the selected malignancies, with definition of TCGA tumor type abbreviations defined. C, Heat map analysis of percent positive samples for designated prostaglandin pathway genes, including PTGER4, PTGS2, PTGES2, and PTGES from the Protein Atlas database.
- Open Access
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 4 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
TPST-1495 confers therapeutic efficacy in mice bearing PGE2-producing tumors. A, PGE2 detected by mass spectrometry in cell culture fluids of tumor cells lines after 24 hours in culture. Results depict six technical replicates. B, PGEM detected by mass spectrometry in urine of tumor-bearing mice from untreated animals (shown in C) approximately 17 days after tumor implantation. Results are representative of one experiment with five biological replicates. Tumor outgrowth (C) and percent TGI [TGI = 100*(Control Volume − Treatment Volume)/Control Volume] (D) measured in mice bearing flank implanted tumors of tumor types shown in the figure. A total of 1 × 106 cells were implanted on day 0 and treatment in mice randomized to assigned groups was initiated when average tumor volume within a tumor line reached approximately 80–100 mm3. Mice were treated with TPST-1495 (100 mg/kg twice a day, orally), E7046 (150 mg/kg every day, orally), PF04418948 (100 mg/kg every day, orally), or Celecoxib (60 mg/kg every day, orally) and followed for outgrowth until vehicle mice reached humane endpoints. Results are representative of two experiments with N = 5 mice per group. Mean and SD are depicted in all graphs and the Student two-sided t test was used to assess significance between individual groups at the last timepoint before mice were sacrificed. **, P < 0.01; *, P < 0.05. Flow cytometry (E) or IHC (F) from CT26 tumors after 14 days of treatment. A total of 1 × 106 CT26 cells were implanted in the flanks of animals and followed until the average was 80–100 mm3. Mice were then treated for 14 days at which time tumors were resected and stained. Results depict one experiment with 8 mice, representative of more than three similar experiments. G and H, Flow cytometry from CT26 tumors resected after 17 days of treatment. Tumors were implanted as in E, treated for 17 days with TPST-1495, and then time tumors were resected and stained for DC1+ dendritic cells (G) or macrophages (H). Results shown in G represent one experiment with 10 mice, representative of multiple similar experiments with an average of 2-fold increase over vehicle, but data depicted are the only replicate that met P < 0.05 statistical cutoff. One datapoint in G met the Gibbs criteria for outliers and was excluded. Results in H represent one experiment of two similar experiments with at least 8 mice. Mean and SD are depicted in all graphs and the Student two-sided t test was used to assess significance between individual groups. ****, P < 0.0001; **, P < 0.01; *, P < 0.05.
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 4 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
TPST-1495 confers therapeutic efficacy in mice bearing PGE2-producing tumors. A, PGE2 detected by mass spectrometry in cell culture fluids of tumor cells lines after 24 hours in culture. Results depict six technical replicates. B, PGEM detected by mass spectrometry in urine of tumor-bearing mice from untreated animals (shown in C) approximately 17 days after tumor implantation. Results are representative of one experiment with five biological replicates. Tumor outgrowth (C) and percent TGI [TGI = 100*(Control Volume − Treatment Volume)/Control Volume] (D) measured in mice bearing flank implanted tumors of tumor types shown in the figure. A total of 1 × 106 cells were implanted on day 0 and treatment in mice randomized to assigned groups was initiated when average tumor volume within a tumor line reached approximately 80–100 mm3. Mice were treated with TPST-1495 (100 mg/kg twice a day, orally), E7046 (150 mg/kg every day, orally), PF04418948 (100 mg/kg every day, orally), or Celecoxib (60 mg/kg every day, orally) and followed for outgrowth until vehicle mice reached humane endpoints. Results are representative of two experiments with N = 5 mice per group. Mean and SD are depicted in all graphs and the Student two-sided t test was used to assess significance between individual groups at the last timepoint before mice were sacrificed. **, P < 0.01; *, P < 0.05. Flow cytometry (E) or IHC (F) from CT26 tumors after 14 days of treatment. A total of 1 × 106 CT26 cells were implanted in the flanks of animals and followed until the average was 80–100 mm3. Mice were then treated for 14 days at which time tumors were resected and stained. Results depict one experiment with 8 mice, representative of more than three similar experiments. G and H, Flow cytometry from CT26 tumors resected after 17 days of treatment. Tumors were implanted as in E, treated for 17 days with TPST-1495, and then time tumors were resected and stained for DC1+ dendritic cells (G) or macrophages (H). Results shown in G represent one experiment with 10 mice, representative of multiple similar experiments with an average of 2-fold increase over vehicle, but data depicted are the only replicate that met P < 0.05 statistical cutoff. One datapoint in G met the Gibbs criteria for outliers and was excluded. Results in H represent one experiment of two similar experiments with at least 8 mice. Mean and SD are depicted in all graphs and the Student two-sided t test was used to assess significance between individual groups. ****, P < 0.0001; **, P < 0.01; *, P < 0.05.
- Open Access
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 3 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
TPST-1495 is more effective than a single EP4 or EP2 antagonists in overcoming PGE2-mediated immune suppression of recovery of cytokine production from human monocytes and T cells. TNFα ELISA from PGE2 blockade assay performed using human whole blood treated with TPST-1495 (A) or E7046 (B) in the presence of 10 nmol/L or 500 nmol/L PGE2. Graphs show one representative donor of 3 donors tested. C–E, IFNγ concentration in supernatants of PGE2 blockade assay performed on magnetically enriched T cells from human PBMC. Cells were treated with various concentrations of EP receptor inhibitors TPST-1495 (C), E7046 (D), or PF04418948 (E), followed by concentrations of PGE2 and CEF peptides as shown in C and D. Cytokine levels in supernatants were determined by bead-based cytokine array analysis. Graphs show data with N = 4 technical replicates from one of four independent experiments. Two different healthy donors were used across these experiments. F, Percent IFNγ production rescue, as normalized to the control (DMSO), from PGE2 Blockade assay supernatants. Magnetically enriched T Cells from human PBMC were treated with increasing amounts of EP1 (Ono-8130) and EP3 (L-798106) inhibitors and subjected to 333 nmol/L PGE2 before stimulation with CEF peptides. Each datapoint represents the average percent recovery from one experiment, with four total experiments shown. G, Percent IFNγ production rescue, as normalized to control with 0 nmol/L PGE2 and 0 nmol/L TPST-1495. Cells obtained as in C–F were treated with increasing TPST-1495 in the presence or absence of 10 mmol/L EP1 inhibitor and 10 mmol/L EP3 inhibitor. Each datapoint represents the average percent recovery from one experiment, with four total experiments shown. Mean and SD are depicted in all graphs and the Student two-sided t test was used to assess significance between individual groups. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05.
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 3 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
TPST-1495 is more effective than a single EP4 or EP2 antagonists in overcoming PGE2-mediated immune suppression of recovery of cytokine production from human monocytes and T cells. TNFα ELISA from PGE2 blockade assay performed using human whole blood treated with TPST-1495 (A) or E7046 (B) in the presence of 10 nmol/L or 500 nmol/L PGE2. Graphs show one representative donor of 3 donors tested. C–E, IFNγ concentration in supernatants of PGE2 blockade assay performed on magnetically enriched T cells from human PBMC. Cells were treated with various concentrations of EP receptor inhibitors TPST-1495 (C), E7046 (D), or PF04418948 (E), followed by concentrations of PGE2 and CEF peptides as shown in C and D. Cytokine levels in supernatants were determined by bead-based cytokine array analysis. Graphs show data with N = 4 technical replicates from one of four independent experiments. Two different healthy donors were used across these experiments. F, Percent IFNγ production rescue, as normalized to the control (DMSO), from PGE2 Blockade assay supernatants. Magnetically enriched T Cells from human PBMC were treated with increasing amounts of EP1 (Ono-8130) and EP3 (L-798106) inhibitors and subjected to 333 nmol/L PGE2 before stimulation with CEF peptides. Each datapoint represents the average percent recovery from one experiment, with four total experiments shown. G, Percent IFNγ production rescue, as normalized to control with 0 nmol/L PGE2 and 0 nmol/L TPST-1495. Cells obtained as in C–F were treated with increasing TPST-1495 in the presence or absence of 10 mmol/L EP1 inhibitor and 10 mmol/L EP3 inhibitor. Each datapoint represents the average percent recovery from one experiment, with four total experiments shown. Mean and SD are depicted in all graphs and the Student two-sided t test was used to assess significance between individual groups. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05.